Status:
UNKNOWN
Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis
Lead Sponsor:
Università degli Studi dell'Insubria
Conditions:
Vaginitis
Eligibility:
FEMALE
Phase:
PHASE2
PHASE3
Brief Summary
We hypothesise that the use of Adelmidrol (Saginil in vaginal cannulas) can reduce the incidence and magnitude of vaginitis in patients affected by gynecologic malignancies.
Eligibility Criteria
Inclusion
- Gynecologic malignancy
- Current administration of chemotherapy
Exclusion
- Colpectomy
- Vaginal cancer
- Vulvar cancer
- Bacterial vaginitis
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01420510
Start Date
September 1 2011
End Date
December 1 2014
Last Update
June 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gynecologic Oncology Unit
Varese, Italy, 21100